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Chapter 23

Amit M Deokar·, MD, MPH,
Amanda J Goodwin, PA-C and
Division of Adolescent Medicine, Department of
Lexington, Kentucky, United States

This chapter has a two-fold objective. One, it addresses
hyperandrogenism and obesity and the complex metabolic aeJ~angeJIIlems
the problem. Clinical management of these co-morbidities is ..,.. ,, ..~...5 ...5
Second, this chapter will aid health care providers with the key ·-'"'·-· .,.,.
diagnosis and intervention to decrease the morbidities in the short as
Method: Systematic review of articles and information on the
published in the last 15 years. Conclusion: Obesity and
patts of Metabolic Syndrome/Polycystic Ovarian Syndrome
Insulin resistance, and Acanthosis Nigricans (HAIR-AN). With
epidemic, the metabolic syndrome and the associated abnormalities
clinical practice and these have a tremendous economic burden on
quality of life.

INTRODUCTION
Obesity in children and adolescents has increased at an alarming Hte in, the last two
decades. Over the years, researchers have acquired a better understanding about the strong
association of obesity in metabolic syndrome (MS, previously knownas tnetabolic syndrome
X) (1). Patients with MS have various metabolic abnormalities that caninclude abnormal
glucose and insulin ratio, insulin resistance, high blood pressure, altered lipid profile, prothrombotic and pro-inflammatory state. Teenagers with MS are predisposed to long term
morbidities, such as early coronary mtery disease, hepatic steatosis, type 2 diabetes, and
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stroke (1). Evidence suggests that an overweight teenager has an 80 percent chance of
continuing to be overweight in the adult life (2).
Approximately 17 percent of children aged 2-19 years are considered overweight based
on a survey by National Health and Nutrition Examination Survey of2003-2004 (3). As noted
earlier, the rate of obesity has doubled in adolescents, who are in the 12-19 year age group
(4). The prevalence of obese and overweight children may be different depending on the
gender and ethnicity. For example, the obesity rates are higher in African Americans,
Hispanic Americans, males, and those living in the southern states (2). The definition of
obesity varies in adolescents when compared to adults due to different proportion of body fat
in boys and girls at different ages (5). Body Mass Index (BMI) is a reliable tool to assess
obesity, because it is easy to obtain and correlates well with the body fat (6). Any adolescent
with a BMI of 30 kg/m2 or 95th percentile for gender and age falls in the overweight
category. They are considered at risk of being overweight if their BMI is between 85th and =
95th percentile. In the US, the economic burden of direct and indirect healthcare cost due to
obesity and co-morbidities is estimated to be well over $ 117 billion annually. As the obesity
rates have doubled and tripled respectively in children and adolescents, so have the health
care costs (7). This impacts the healthcare burden directly.
Obesity and hyperandrogenism (HA) are strongly associated in patients who have been
diagnosed to have polycystic ovarian syndrome (PCOS)/HA/MS. This article addresses their
relationship with one another and specific management options. A subset of (PCOS) includes
hyperandrogenism, insulin resistance and acanthosis nigricans, abbreviated as HAIR-AN
(8,9). Historically PCOS was described based on findings of multiple cysts in the ovaries,
irregular or no menstrual periods, and hirsuitism. However, absence of ovarian cysts does not
rule out this syndrome (10). Women with high androgen levels have associated HAIR-AN
features in about 5-10 percent of cases (11). The onset of PCOS/HAIR-AN may occurs in
adolescent years and the diagnosis is likely to be delayed until early adulthood (8,9).

PATHOPHYSIOLOGY
As PCOS/HAIR-AN is being studied more over the last two decades, different theories
have been proposed to explain the features of the syndrome, including obesity. The primary
problem in HA appears to be due to an altered hypothalamo-pituatary-ovarian axis. The
anovulation and thus abnormal or absence of menstrual periods is from a persistent
leutenizing hormone (LH) surge and its high concentration in the blood. There is also an
increased GnRH surge as the negative feedback from estrogen and progesterone is ineffective
due to relative hypothalamic insensitivity. The LH surge results in increased production of
androgens. The level of follicle stimulating hormone (FSH) is less when compared to the LH
resulting in decreased enzymatic (aromatase) conversion of androgen to estrogen and thus
anovulation.
Another key association of HA is hyperinsulinsm. This is due to peripheral insulin
resistance, which can result in a hyperglycemic state. The level of sex hormone binding
(SHBG) is decreased due to the high insulin levels and consequently there is a rise in
level (8). Insulin also increases the androgen production by directly
cells (12). Both hyperinsulinism and HA predispose an individual to
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have an athrogenic lipid profile. Total cholesterol, triglycerides (TG) levels are also elevated.
Increased activity of the enzyme lipase affects the cholesterol metabolism and could result in
a decreased level of the high density lipoprotein-cholesterol (HDL-C) (13). Another
postulated mechanism for HAIR-AN is a genetic mutation of the insulin receptor (tyrosine
kinase domain) (9).
Effects of HA can be multi-fold. Even though jncrea:srd a11~rogen production in women
is associated with obesity, one study in 2002 by Gapstur et al ( 14) in obese men have found to
have lower testosterone and dehydroepiandroterQ):l~ . sulf~tr (J)f:lf.A.S) l~yels. J-.J:igh androgen
levels in children and adolescents are linked to precoqious Pl.t\)erty, ~cceler~ted bqne growth,
height, features of PCOS, and are more cqmmoply srr.R. i!:li op~~~•.. sJ.Ibj~C:.ts ic;ompared to nonobese. In pre-pubertal obese children the leve]pfDHJ3f\.S isp~en i e]eyated(l4):
Recently, researchers have looked at the <effec;.ts of prgteinsJi~f adipcmecti11, resistin,
leptin, and TNF -a on the fat metabolism, peripher~I il1sJ.lli):l ..l'rsi~~~):lcf.' ~pg enet·gy .expenditure
(15). Resistin is produced by the mature visceral and~.vbcut.~peous~qipocY:~rs anginfluences
insulin sensitivity. Adiponectin and leptin, also secrete<i.Jro1llcfhe a~ig?cytfs, have similar
roles (16). A recently published study by Shin et al (17) sugg~~tedq£~sity ~Ban infl~mmatory
process due to findings of increased levels of C-reactive prot~i.p (y~.J ~ng. }'NFf?.V.nd in
obese children. The adiponectin level was found to be muc.hJo\'t'r£COJ1f~Rtratig):linthese
children. Retinol Biding Protein 4 (RBP4) is present in omentalallg/ ~'-lbfVta~fO'-l.s fat andis
expressed more in women with PCOS (18). The high Ievels. pf.an~E89.rg ~):lg fe~~~wes of
metabolic syndrome have shown to normalize in post-menarchr .p bese ~dole~cents after
weight reduction (19).

DIAGNOSTIC CRITERIA
A standard list of the diagnostic criteria for MS in children and iadolescents .·. is still
lacking. However, a modified diagnostic criteria for childrenusing tlleNCEJ>criteria anddata
from the National Health and Nutrition Examination Survey (NflAN'l~§, 198&..,94) is widely
used. The National Cholesterol Education Program (NCEP) and the.A.dult Treatment Panel III
(ATP III) include at least 3 of 5 of the following criteria for the diagn9sis ofMS in adults
(1 ,2,20,21).
~I

•
•
•
•
•
•
•

Abnormal lipid panel: Hypertriglyceridemia ( >J50 mg/dl) and low HDL-C
(<40mg/dl in males and <50 in females).
High fasting glucose level. Hyperglycemic state i~ definr~ as fasting glucose level of
100 mg/dl or more.
Elevated blood pressure, systolic, diastolic, or both using reference ranges. From
example, blood pressure of > 135/85 mmHg is considered abnormal.
Increased waist circumference/abdominal girth. BMI is fairly reliable in assessing
obesity in children.
High insulin resistance (criterion in children).
The World Health Organization (WHO) criteria required elevated insulin or glucose
level(> llOmg/dl) in addition to at least two of the following:[2]
Abdominal obesity
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•
•
•

Waist size >94 em or waist to hip ratio of>0.9
Triglycerides > 150 mg/dl or HDL <35 mg/dl
Blood pressure > 140/90 mmHg.

HAIR-AN is a clinical diagnosis and includes the following, in addition to criteria
mentioned above (9):
a)

Acne, hirsuitism, temporal balding, clitoromegaly, and deepening of voice
(suggestive ofhigh androgen level).
b) Acrochordons (skin tags), acanthosis nigricans (usually found on the neck, axillae,
and back). These are suggestive of insulin resistance and altered hormonal levels.

SUGGESTED WORKUP
Anthropometric measurement, vital signs, with a complete history and physical exam
(including genital) is recommended. A detailed family, past medical, and medication history
should also be documented. Laboratory data that may be useful includes, fasting levels of
insulin, glucose (complete metabolic panel to assess liver and renal function), lipid panel,
glucose/insulin ratio, HgAlc, and AM cortisol level. Oral glucose tolerance test (2 hour) is
also recommended to document hyperglycemic state. One test that has high sensitivity and
specificity is the euglycemic hyperinsulinemic clamp. This may be impractical in a clinical
setting due to the time consuming and complex nature of the test (9). A thorough endocrine
evaluation should include thyroid function tests, serum prolactin, DHEA-S, am 17hydroxyprogesterone (17-0HP),SHBG level, and free and total testosterone. IGF-1 level may
be helpful in a suspected growth hormone producing tumor (22).
In order to establish the diagnosis of PCOS, the presence of multiple ovarian cysts is not
necessary. Likewise, an abdominal/pelvic ultrasound detection of multiple ovarian cysts does
not confirm that diagnosis either. Occasionally a computed tomography (CT) or an MRI of
the abdomen/pelvis may be necessary in situations where there are progressive signs of
hyperandrogenism (22).

OUTCOME
Metabolic syndrome (PCOS and HAIR-AN subset) in children can lead to potentially
complicated shmt and long term medical problems. This exhaustive list includes but is not
limited to the following (6):
•
•
•
•

Distorted body image and perception
Low self-esteem and depression
Acne
Obesity associated problems like snoring, obstructive sleep apnea, disordered sleep,
gastro esophageal reflux disease (GERD), gall stones, joint pain, exercise
intolerance, features of diabetes, coronary artery disease, and skin changes, etc.
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Amenorrhea (predisposing to subsequent inadequate bone mineralization) and
possibly infertility.

TREATMENT
The timeframe for the diagnosis of metabolic
treatment varies from patient to patient and can be
approach is often required to address the metabolic as
associated with this syndrome. reatment should be
abnormalities as well (6,9 ,23 ). It is important for the .."'"'"·•vcu
concerns that teenagers may have when it relates to "v''"'<'u"
developmental stage where bodily appearance plays an imomiar1t1·6Ie
skin related problems such as acanthosis nigricans, acne,
troubling (22). This can affect their self-esteem directly.
low threshold for referring these teenagers to counseling

Although compliance can play a big role with this
most favored and successful mode of treatment in obese ua•·""'""Weight loss can dramatically improve the ovarian function
androgens (24 ). Different dietary changes such as caloric
with increased protein intake have been previously studied.
available if restriction of carbohydrates is better than that of fat
to use the expertise of a dietician or nutritionist who can
individuals.

MEDICATION
Typically,, in addition to the lifestyle modification,
combination of one or more of these therapies such
agents, combined hormonal contraceptives,
alternative medicine treatment options. As pati of a
counseling is very crucial.

Biguanide: Metformin (trade names such
Rhiomet®), a pregnancy
category B drug, has traditionally been used in type 2 diabetes mellitus (DM). From a
glycemic stand point, Metformin interferes with the hepatocyte mitochondrial respiratory
oxidative process and decreases gluconeogenesis. This however, is not a complete blockade
of gluconeogenesis. It also facilitates the glucose transpoti in tissues such as the skeletal
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muscles, by activating the enzyme tyrosine kinase (TK) on the insulin receptors and
enhancing the glucose transporter system. Some of this action is also on the adipocytes. It
also acts against the gluconeogenic effects of glucagon. Metformin is particularly useful in
obesity associated with HA. Due to its insulin lowering effect, there is a consequent decrease
in the free and total testosterone and an increase in the estradiol level (25). This has a
beneficial effect on ovulation, hirsuitism and acne.
As obesity is strongly associated with cardiovascular morbidity and mortality, metformin
has an added benefit of being cardioprotective. It has shown to decrease the free fatty
oxidation, which helps improve the insulin sensitivity as well. It may also help lower the total
cholesterol (TC), very low density lipopoprotein cholesterol (VLDL-C), low density
lipoprotein cholesterol (LDL-C), and increase the high density lipoprotein cholesterol (HDLC). It also lowers the platelet aggregation and adhesion, and decreases th~ levels of tissue
plasminogen inhibitor 1 and von Willebrand factor. This has a positive effect on homeostasis
(26). It can induce vascular relaxation and reduce the oxidative stress (25,26). A combination
of flutamide (an androgen receptor blocker) and metformin with an addition of drosperinone
(a 4th generation progesterone) has shown to decrease abdominal fat (27).
Usual side effects .from tnetformin may include gastrointestinal symptoms such as
nausea, flatulence and .• ciiarrhea..'fhese may be reduced by taking it with food. Treatment may
be started with a single i ci~iJy.do~~·' preferably at a lowest possible dose. It may then be
increased to a twice daily dos~. It is nqt recommended to go over the maximum dosage of
2.25 grams/day (25). Qne mtJstbe aware of the potential toxicity from metfromin that
includes lactic acidosis if1 pre situ;:ttions. Metformin is fairly safe for the mother and baby
during pregnancy and lactatior1 (28).
Thiazolidinediones: . Rosiglij*zone is an insulin sensitizing agent, whose action on the
peroxisome proliferator-actiyated r:e<;eptor (PP AR ) on the adipocytes improves glucose
transport into the cell by increasing the adiponectin secretion (29). In studies done earlier on
overweight women with PCOS., there was a decrease in the insulin resistance and return of
ovulation as indicated by regular menses. The SHBG level also shows an increase that helps
with the ovulation. Some of the side effects include weight gain and cardiac failure in
susceptible individuals (30).

REGULATION OF THE HORMONAL/ANDROGEN IMBALANCE AND USE
OF ORAL CONTRACEPTIVES
Combination birth control pills (BCP' s) are the cornerstone in the treatment of HA. Their
mechanism of action includes the following:
•
•
•

Increase the SHBG production and level: This allows a reduction of free testosterone.
Suppress LH: Decreases androgen production from the ovaries.
Anti-minerelocorticoid activity: Certain progestins such as Drosperinone have low
androgenic activity and are generally preferred in HA. The brand name
contraceptives Yasmin® and Ortho-Tri-Cyclen® contain Drosperinone.
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The effects of combination BCP's include normalization of menses and a decrease in acne
and hirsuitism (22). In addition to the above, other pharmacologic agents have been tried in
HA states are cyproterone acetate, finastreride, glucocorticoid, such as prednisone (patients
with late onset congential adrenal hyperplasia (CAH) having PCOS features), and
spironolactone.

SURGICAL OPTIONS
Bariatric Surgery: A decrease in obesit)'~relat~~ 11lof9i~i}y p~~ . pee~ )Y~ll~g~ul)1e11tecl in
individuals that have undergone Roux~en- Y .gastriS iPypas!) surg7r,0• AlJ:~gugh /this · · is an
optional procedure that has been evaluatedl'Il.ostly.i11.01orpt~lyop.7~·~ i ~~gH~.,tp7 ·RWgeli~es are
quite conservative for the adolescent ·popt~lati()lJ.MorpicilY op7se te7~~ger~, Th0h().} ~. ~:Vt:: failed
the non-surgical approach may be considered fora ga~tric b0jJI.lSS stl9~.~fY· ~tper j~~J.ifications
in addition to the above includes a BMI of 40 ·kg/ro2 or .tn()r~, Pll0.sic.~ti~~g g~0Snos()pial co
morbidities from obesity (31 ). Bariatric surgery intended/ to re~Hlt in , Th0eig~~ <loss can
positively impact obesity, PCOS, and reverse anovulation. Tll~ ris~~ : ff?l1l gp.7si~0 ~l,lring
pregnancy in morbidly obese teens is also decreased by the procedur~p 1). ~\l to ~ 0ear wait
post operatively for becoming pregnant is usually recommended .. .As<~~· ~f7?~g? P7P()tential
complications from this surgical procedure, careful multidisciplinary evaltil.lli()n.f()tthe 11eed
for surgery is needed.

COMPLEMENTARY AND ALTERNATIVE MEDICINE
Alternative approaches ·in the treatment of PCOS have beenr~ce11~lt/P~igigR pop~larity .
In view of side effects from the traditional medical and surgical trea.ttnent,ir,~searsners have
looked at the benefits of acupuncture, a traditional form ofChi11~se• l11•7~iqig7.· .Afupuncture
has been shown to modulate neuro-endocrine systems that resultsi11. 1?)Yt:lf~~g,g:[J~gincr~ased
sympathetic tone in individuals with PCOS. By releasing B-endorphins<the technique of
acupuncture can directly influence the HPA axis and lower the co11:isol<t~c1J_,l)i}.~yels (32). As
a result, its beneficial effects on metabolic, ovulation, and other neurq-endocrinal endogenous
systems can positively influence the features of PCOS/HA. ()ther forms qf alternative
medicine such as homeopathy, Ayurveda, diet supplements,>and hypnotherapy have been
tried to treat obesity in adults with some encouraging results eyenthough some are not very
convincing (33).

FEDERALIST ATE PROGRAM
The CDC (Center for Disease Control and Prevention), the Division of Nutrition and
Physical Activity (DNPA) and the health departments of 28 states have established the
Nutrition and Physical Activity Program to Prevent Obesity and Other Chronic Diseases
(NPAO) since 1999 using the social ecological model (34 ). Healthcare providers are
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encouraged to contact their individual health departments to learn more about the program,
where available.

CONCLUSIONS
Metabolic syndrome, hyperandrogenism, and PCOS are integral part of complex
metabolic abnormalities that have a great impact on the health and general well-being of an
individual. The diagnosis is often late and this adds to the economic burden from obesity
related problems. The following key points will aid the healthcare provider with the timely
diagnosis of HA/MS/PCOS and appropriate interventions.
•
•
•
•
•

•

•

Healthcare provider awareness of obesity in childhood and adolescence.
Utilizing diagnostic criteria and/or clinical diagnosis of PCOS/HA/MS. One may
refer to the NCEP, NHANES, ATP III, WHO diagnostic criteria.
A complete history, including that of the individual, family, past, and medications.
Complete physical exam. As noted earlier, the diagnosis of HAIR-AN is clinical.
Laboratory and radiological work up. The list includes fasting insulin, glucose
(complete metabolic panel to assess liver and renal function), lipid panel,
glucose/insulin ratio, HgAlc, and AM cmtisol level. Oral glucose tolerance test (2
hour), thyroid function tests, serum prolactin, DHEA-S, am 17-hydroxyprogesterone
(17-0HP), SHBG level, free and total testosterone, IGF-1 level are also
recommended.
Management that includes medical, surgical, lifestyle modification techniques, and
appropriate referrals to other sub-specialty providers for addressing associated co
morbidities. Keeping in mind that some patients may desire to utilize alternative and
complimentary medicine options as well.
Multidisciplinary approach that includes, the primary care provider, sub-specialist,
social worker, nutritionist, and counselor/psychologist.
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